Page 394 - கடுமையானது எடுப்போசை சுவாச நோய்க்குறி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
PE confirma 2 965 novos casos da Covid-19, sendo segundo maior registro diário desde início da pandemia
diariodepernambuco.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from diariodepernambuco.com.br Daily Mail and Mail on Sunday newspapers.
Pernambuco registra quase 3 mil novas confirmações de covid-19 e atinge 361 470 casos
uol.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uol.com.br Daily Mail and Mail on Sunday newspapers.
Com 2 965 confirmações, Pernambuco tem 2º maior número de novos casos da covid-19 em 24h
uol.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uol.com.br Daily Mail and Mail on Sunday newspapers.
South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine
The current pandemic of novel coronavirus disease 2019 (COVID-19) was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has undergone numerous mutations in its genome to emerge as different variants. As of now, a dozen vaccines have received emergency use authorization, and many countries around the world have initiated mass vaccination campaigns.
A new preprint research paper posted to the
medRxiv server reports on vaccine resistance data that pushes the end of the pandemic further away.
Variants of concern and spike mutations
Most vaccines now in use or being developed focus on generating antibodies to the viral spike protein, which mediates host cell entry and infection. This is based on the strong correlation between neutralizing antibodies to the spike and protective immunity.
CAL20.C SARS-CoV-2 variant skyrocketing in California evades host immune response
The effect of different neutralizing antibodies, both vaccine-elicited and from convalescent sera, suggests new variants are emerging that can evade the human immune response.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to host cells via its spike protein, which has two parts, the S1 and S2 subunits. The S1 subunit has the receptor-binding domain (RBD) and the N-terminal domain (NTD). The RBD binds to the host angiotensin-converting enzyme 2 (ACE2) to infect host cells.
Neutralizing antibodies are produced against both the RBD and NTD by infected and vaccinated individuals. Some RBD-specific monoclonal antibodies are currently under clinical trials or approved for use to treat COVID-19 patients.